Reports
Reports
Sale
The global cholera vaccines market size attained a value of USD 120.62 million in 2023, driven by growing demand for Dukoral. The market is anticipated to grow at a CAGR of 12% during the forecast period of 2024-2032 to attain a value of USD 334.50 million by 2032.
Based on product, Dukoral is predicted to hold a significant share of the market. The increasing demand for the product can be attributed to the fact that Dukoral is the only oral (drinkable) vaccine available in the market, which provides protection against cholera and diarrhoea caused by Enterotoxigenic E. coli (ETEC), the most common cause of diarrhoea for travellers to many parts of the world. This factor is contributing to the growth of the segment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Further, Dukoral can be given to adults and children 2 years of age and older. Apart from this, the growing population in the cholera endemic region as well as the individuals travelling to the said region are also anticipated to propel the segment growth in the coming years.
The Asia Pacific region is estimated to hold a substantial share of the global cholera vaccines market in the forecast period. This growth can be attributed to the increasing prevalence of cholera in the region. In addition, the increased government investments supporting the immunisation process are also anticipated to propel the market growth in the forecast period. Moreover, the growing awareness pertaining to the vaccines and the increased availability of oral vaccines in the region are also predicted to bolster the market growth in the coming years. The adoption of water, sanitation, and hygiene practices has proven to be effective in protecting the population, along with the use of oral cholera vaccines (OCVs).
Meanwhile, the demand for cholera vaccines in North America is also expected to witness a considerable growth over the forecast period owing to the increased government expenditure on immunisation programmes in the region. The increasing number of travellers in North American countries, including the United States and Canada, are significantly contributing to the rising vaccine demands. In June 2016, the Food and Drug Administration (FDA) approved Vaxchora (PaxVax, Inc.) for United States (US) travellers, as no cholera vaccine was available to help protect them until that time. Vaxchora™ (CVD 103-HgR), an oral live attenuated vaccine, is the first and only cholera vaccine available in the United States.
Cholera refers to an acute diarrhoeal illness, which is caused by an infection in the intestine. It is spread through the ingestion of water or food that is contaminated with the bacterium Vibrio cholerae. An estimated number 1.3 to 4.0 million cases of cholera are reported every year, with 21,000 to 1,43,000 deaths worldwide due to cholera. The cholera vaccines are essential in controlling the spread of cholera, which is recommended by the WHO for individuals travelling to cholera affected regions, as well as people residing in such areas.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By product, the cholera vaccines market is divided into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
According to the WHO statistics, an estimated 1.3 to 4.0 million cases of cholera are reported every year. The disease impacts children as well as adults and can result in death, if left untreated. Cholera is linked to the decreased availability of clean water and sanitation facilities. In this regard, the WHO Global Task Force on Cholera Control (GTFCC), a programme aimed at controlling the spread of cholera by 2030, was launched to reduce the mortality risk associated with the disease by 90% in cholera prone areas such as Asia and Africa. This is leading to the increased demand for cholera vaccines around the globe. In addition, rising investments by the governments to develop efficient vaccines to treat cholera are expected to further propel the cholera vaccines market forward. As cholera is a public health threat, the governments are making significant investments to provide improved water and sanitation facilities to the least privileged population, that remains largely affected by the disease due to poor sanitation. Moreover, the increasing concerns associated with cholera outbreaks and the emergence of new strains that might be of greater severity are leading to a rise in research and development activities by both government and private bodies. These factors are anticipated to positively impact the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report gives a detailed analysis of the following key players in the global cholera vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model and SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cholera Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cholera Vaccine Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cholera Epidemiology (2016-2031)
5.3 Europe Cholera Epidemiology (2016-2031)
5.4 Asia-Pacific Cholera Epidemiology (2016-2031)
5.5 Latin America Cholera Epidemiology (2016-2031)
5.6 Middle East & Africa Cholera Epidemiology (2016-2031)
6 Global Cholera Vaccine Market Overview
6.1 Global Cholera Vaccine Market Historical Value (2017-2023)
6.2 Global Cholera Vaccine Market Forecast Value (2024-2032)
7 Global Cholera Vaccine Market Landscape
7.1 Cholera Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cholera Vaccine: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Cholera Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cholera Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cholera Vaccine Market Segmentation
11.1 Global Cholera Vaccine Market by Product
11.1.1 Market Overview
11.1.2 Dukoral
11.1.3 Shanchol
11.1.4 Vaxchora
11.1.5 Euvichol
11.1.6 Others
11.2 Global Cholera Vaccine Market by End User
11.2.1 Market Overview
11.2.2 Hospitals & Clinics
11.2.3 Research and Academic Laboratories
11.2.4 Others
11.3 Global Cholera Vaccine Market by Region
11.3.1 Market Overview
11.3.2 North America
11.3.3 Europe
11.3.4 Asia Pacific
11.3.5 Latin America
11.3.6 Middle East and Africa
12 North America Cholera Vaccine Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cholera Vaccine Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cholera Vaccine Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cholera Vaccine Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cholera Vaccine Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Sanofi-aventis Groupe
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Emergent BioSolutions Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Valneva SE
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 GlaxoSmithKline plc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Intervet Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 EuBiologics Co., Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Celldex Therapeutics.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Services Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Cholera Vaccine - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Globally, cholera vaccines market reached a value of USD 120.62 million in 2023.
The market is projected to expand at a CAGR of 12% from 2024 to 2032, growing to USD 334.50 million by 2032.
The major drivers of the industry, such as the increased demand for cholera vaccines in the cholera endemic region, growing pharmaceutical industry, rising demand for cholera vaccines for travellers, and the rising incidences of cholera, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the rising investments in research and development of vaccines by the leading life sciences companies.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant products considered in the market report include Dukoral, Shanchol, Vaxchora, and others.
The major players in the industry are Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Intervet Inc., EuBiologics Co., Ltd., and others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.